Erectile Dysfunction - Pipeline Review, H2 2022
Erectile Dysfunction - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2018, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 6, 3, 1, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Apricus Biosciences Inc
Aquestive Therapeutics
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Biozeus
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Hanmi Pharmaceuticals Co Ltd
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
iX Biopharma Ltd
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
N4 Pharma Plc
NAL Pharmaceuticals Ltd
Nanoform Cardiovascular Therapeutics Ltd
Palatin Technologies Inc
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Yungjin Pharm Co Ltd
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction - Companies Involved in Therapeutics Development
Apricus Biosciences Inc
Aquestive Therapeutics
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Biozeus
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Hanmi Pharmaceuticals Co Ltd
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
iX Biopharma Ltd
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
N4 Pharma Plc
NAL Pharmaceuticals Ltd
Nanoform Cardiovascular Therapeutics Ltd
Palatin Technologies Inc
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Yungjin Pharm Co Ltd
Erectile Dysfunction - Drug Profiles
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BZ-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yonkenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Dec 15, 2017: Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2015
Nov 22, 2017: Initiator Pharma receives positive result from the toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 31, 2017: Humanetics Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients
Oct 26, 2017: Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 10, 2017: Apricus Biosciences to Present at the 2017 BIO Investor Forum
Oct 10, 2017: N4 Pharma: Sildenafil PCT Update
Sep 07, 2017: A busy summer is providing valuable and Positive Results from the first Maximum tolerated dose toxicology for drug Candidate IPED2015
Aug 31, 2017: Apricus Biosciences Announces FDA Acknowledgement of Vitaros Class 2 NDA Resubmission
Aug 29, 2017: Apricus Biosciences Files NDA Resubmission for Vitaros
Aug 23, 2017: iX Biopharma Provides Update on PheoniX
Jul 27, 2017: N4 Pharma: Filing of Patents and Sildenafil Update
Jul 27, 2017: N4 Pharma: Update on Sildenafil clinical plans
May 11, 2017: iX Biopharma Files for the Registration of PheoniX (Sublingual Sildenafil)
May 09, 2017: Synthesis route for IPED2015 Selected
May 04, 2017: Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development for Erectile Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1 2018
Erectile Dysfunction - Pipeline by Aquestive Therapeutics, H1 2018
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2018
Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1 2018
Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2018
Erectile Dysfunction - Pipeline by Biozeus, H1 2018
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2018
Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2018
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2018
Erectile Dysfunction - Pipeline by IntelGenx Corp, H1 2018
Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1 2018
Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1 2018
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Erectile Dysfunction - Pipeline by N4 Pharma Plc, H1 2018
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2018
Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2018
Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1 2018
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Suda Ltd, H1 2018
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H1 2018
Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018 (Contd..1), H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018 (Contd..2), H1 2018
Erectile Dysfunction - Discontinued Products, H1 2018List of Figures
Number of Products under Development for Erectile Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Research Methodology
The research study released with title "Erectile Dysfunction - Pipeline Review, H2 2022" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Erectile Dysfunction Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Erectile Dysfunction Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Erectile Dysfunction Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Erectile Dysfunction Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Erectile Dysfunction - Pipeline Review, H2 2022" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
